Primary Aldosteronism: a Common Cause of Resistant Hypertension

Overview

Journal CMAJ

Date 2017 Jun 7

PMID 28584041

Citations 22

Authors

Gregory A Kline

Ally P H Prebtani

Alexander A Leung

Ernesto L Schiffrin

Affiliations

Soon will be listed here.

Citing Articles

Discordance between adrenal vein sampling and imaging: the role of unilateral cortisol excess.

Grundy M, Leung A, Hyrcza M, Pasieka J, Chan D, Przybojewski S Eur J Endocrinol. 2025; 192(3):191-201.

PMID: 39960854 PMC: 11894521. DOI: 10.1093/ejendo/lvaf019.

Clinical practice guideline for the management of hypertension in China.

Chin Med J (Engl). 2024; 137(24):2907-2952.

PMID: 39653517 PMC: 11706600. DOI: 10.1097/CM9.0000000000003431.

Cutoff Values of Aldosterone and the Aldosterone-Renin Ratio for Predicting Primary Aldosteronism in Patients with Resistant Hypertension: A Real-Life Study.

da Silveira J, Sangaleti C, Camacho C, Maciel A, Irigoyen M, Macedo T J Cardiovasc Dev Dis. 2024; 11(10).

PMID: 39452270 PMC: 11508297. DOI: 10.3390/jcdd11100299.

Plasma aldosterone concentrations elevation in hypertensive patients: the dual impact on hyperuricemia and gout.

Song S, Cai X, Hu J, Zhu Q, Shen D, Ma H Front Endocrinol (Lausanne). 2024; 15:1424207.

PMID: 39140032 PMC: 11319118. DOI: 10.3389/fendo.2024.1424207.

Correlation between plasma aldosterone concentration and bone mineral density in middle-aged and elderly hypertensive patients: potential impact on osteoporosis and future fracture risk.

Song S, Cai X, Hu J, Zhu Q, Shen D, Heizhati M Front Endocrinol (Lausanne). 2024; 15:1373862.

PMID: 38808106 PMC: 11130431. DOI: 10.3389/fendo.2024.1373862.

References

Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T . Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004; 27(3):193-202. DOI: 10.1291/hypres.27.193. View

Mazzuco T, Grunenwald S, Lampron A, Bourdeau I, Lacroix A . Aberrant hormone receptors in primary aldosteronism. Horm Metab Res. 2010; 42(6):416-23. DOI: 10.1055/s-0029-1243602. View

Calhoun D, Nishizaka M, Zaman M, Thakkar R, Weissmann P . Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002; 40(6):892-6. DOI: 10.1161/01.hyp.0000040261.30455.b6. View

Mulatero P, Stowasser M, Loh K, Fardella C, Gordon R, Mosso L . Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab. 2004; 89(3):1045-50. DOI: 10.1210/jc.2003-031337. View

Born-Frontsberg E, Reincke M, Rump L, Hahner S, Diederich S, Lorenz R . Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn's Registry. J Clin Endocrinol Metab. 2009; 94(4):1125-30. DOI: 10.1210/jc.2008-2116. View

Tanase-Nakao K, Naruse M, Nanba K, Tsuiki M, Tagami T, Usui T . Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism. Clin Endocrinol (Oxf). 2014; 81(5):665-70. DOI: 10.1111/cen.12497. View

Stowasser M, Gordon R, Gunasekera T, Cowley D, Ward G, Archibald C . High rate of detection of primary aldosteronism, including surgically treatable forms, after 'non-selective' screening of hypertensive patients. J Hypertens. 2003; 21(11):2149-57. DOI: 10.1097/00004872-200311000-00025. View

Gallay B, Ahmad S, Xu L, Toivola B, Davidson R . Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001; 37(4):699-705. DOI: 10.1016/s0272-6386(01)80117-7. View

Kline G, Pasieka J, Harvey A, So B, Dias V . Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes. Ann Surg Oncol. 2013; 20(7):2274-8. DOI: 10.1245/s10434-013-2871-3. View

10.

Rossi G, Cesari M, Cuspidi C, Maiolino G, Cicala M, Bisogni V . Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013; 62(1):62-9. DOI: 10.1161/HYPERTENSIONAHA.113.01316. View

11.

Briet M, Schiffrin E . Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010; 6(5):261-73. DOI: 10.1038/nrneph.2010.30. View

12.

Nanba K, Tamanaha T, Nakao K, Kawashima S, Usui T, Tagami T . Confirmatory testing in primary aldosteronism. J Clin Endocrinol Metab. 2012; 97(5):1688-94. DOI: 10.1210/jc.2011-2504. View

13.

Iwakura Y, Morimoto R, Kudo M, Ono Y, Takase K, Seiji K . Predictors of decreasing glomerular filtration rate and prevalence of chronic kidney disease after treatment of primary aldosteronism: renal outcome of 213 cases. J Clin Endocrinol Metab. 2013; 99(5):1593-8. DOI: 10.1210/jc.2013-2180. View

14.

Williams B, MacDonald T, Morant S, Webb D, Sever P, McInnes G . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015; 386(10008):2059-2068. PMC: 4655321. DOI: 10.1016/S0140-6736(15)00257-3. View

15.

Kayser S, Dekkers T, Groenewoud H, van der Wilt G, Carel Bakx J, van der Wel M . Study Heterogeneity and Estimation of Prevalence of Primary Aldosteronism: A Systematic Review and Meta-Regression Analysis. J Clin Endocrinol Metab. 2016; 101(7):2826-35. DOI: 10.1210/jc.2016-1472. View

16.

Pruthi D, McCurley A, Aronovitz M, Galayda C, Karumanchi S, Jaffe I . Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol. 2013; 34(2):355-64. PMC: 3951242. DOI: 10.1161/ATVBAHA.113.302854. View

17.

Milliez P, Girerd X, Plouin P, Blacher J, Safar M, Mourad J . Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005; 45(8):1243-8. DOI: 10.1016/j.jacc.2005.01.015. View

18.

Benham J, Eldoma M, Khokhar B, Roberts D, Rabi D, Kline G . Proportion of Patients With Hypertension Resolution Following Adrenalectomy for Primary Aldosteronism: A Systematic Review and Meta-Analysis. J Clin Hypertens (Greenwich). 2016; 18(12):1205-1212. PMC: 8031514. DOI: 10.1111/jch.12916. View

19.

Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky Jr J . Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003; 17(5):349-52. DOI: 10.1038/sj.jhh.1001554. View

20.

Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R . Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008; 168(1):80-5. DOI: 10.1001/archinternmed.2007.33. View